| Old Articles: <Older 6591-6600 Newer> |
|---|
 |
The Motley Fool
August 18, 2010
Charly Travers & Seth Jayson |
Will United Therapeutics Burn You? United Therapeutics is cash flow-positive and has mostly been over the past few years. That's investment nirvana for biotech shareholders. This is a rare beast worthy of additional research.   |
The Motley Fool
August 18, 2010
Travers & Jayson |
Will Endo Pharmaceuticals Holdings Burn You? Endo Pharmaceuticals Holdings is cash flow-positive, and has been for quite some time. That's investment nirvana for biotech shareholders. |
The Motley Fool
August 18, 2010
Travers & Jayson |
The Most Important Thing About Human Genome Sciences Is Human Genome Sciences on strong financial footing? Take a look. |
The Motley Fool
August 18, 2010
Travers & Jayson |
Interested in Elan? Start Here! You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big. |
The Motley Fool
August 18, 2010
Travers & Greer |
Dendreon's Big Pharma Future Dendreon has had success with its prostate cancer treatment Provenge. What does Provenge's success mean for the future of Dendreon? |
The Motley Fool
August 18, 2010
Travers & Jayson |
Will Dendreon Burn You? You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big. Don't start with the science; ignore the sexy story, and look at the cold, hard cash. How does Dendreon stack up? |
The Motley Fool
August 18, 2010
Jordan DiPietro |
How Long Will Merck's Dividend Last? Check out how Merck stacks up in this article. |
The Motley Fool
August 18, 2010
David Meier |
Alcon: Deflation Fighter Alcon could be a good candidate to keep you ahead of the game. |
The Motley Fool
August 18, 2010
David Meier |
Stryker: Deflation Fighter Compared to competitors Zimmer and Medtronic, Stryker appears better prepared to handle a deflationary environment. |
The Motley Fool
August 18, 2010
Luke Timmerman |
Life Technologies Competes for Cheap DNA Sequencing In the race to cheaper gene sequencing. |
| <Older 6591-6600 Newer> Return to current articles. |
